^
    Back
    Association details:
    Biomarker:DLAT overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases

    Published date:
    10/13/2023
    Excerpt:
    HCC with high DLAT expression was predicted to be more sensitive to sorafenib treatment.
    DOI:
    1038/s41598-023-43835-y